Amgen to release phase 3 trial results of three drugs in second half of 2009

THOUSAND OAKS, Calif. Amgen plans to release data from five phase 3 trials of three new drugs in the second half of this year.

In a conference call with reporters Tuesday, the company said it would release results of two trials of the cancer drug Vectibix (panitumumab), two trials of the cancer drug denosumab and a trial to determine the effect of treating anemia with Aranesp (darbepoetin alfa) on mortality and cardiovascular events in patients with chronic kidney disease and Type 2 diabetes not on dialysis.

The conference call included background information about the trials from Amgen chief medical officer and head of global development Sean Harper; VP global development, hematology and oncology Roy Baynes; VP global oncology development and oncology therapeutics David Chang; and executive medical director for global development and nephrology Preston Klassen.